company background image
IVC

Invacare NYSE:IVC Stock Report

Last Price

US$1.36

Market Cap

US$48.5m

7D

-5.6%

1Y

-83.1%

Updated

29 Jun, 2022

Data

Company Financials +
IVC fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

IVC Stock Overview

Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide.

Invacare Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Invacare
Historical stock prices
Current Share PriceUS$1.36
52 Week HighUS$8.83
52 Week LowUS$0.80
Beta0.85
1 Month Change44.68%
3 Month Change-3.55%
1 Year Change-83.15%
3 Year Change-73.75%
5 Year Change-89.62%
Change since IPO-48.80%

Recent News & Updates

Shareholder Returns

IVCUS Medical EquipmentUS Market
7D-5.6%3.4%1.6%
1Y-83.1%-24.5%-20.8%

Return vs Industry: IVC underperformed the US Medical Equipment industry which returned -25.7% over the past year.

Return vs Market: IVC underperformed the US Market which returned -20.4% over the past year.

Price Volatility

Is IVC's price volatile compared to industry and market?
IVC volatility
IVC Average Weekly Movement14.0%
Medical Equipment Industry Average Movement10.4%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: IVC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: IVC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
18853,000Matt Monaghanhttps://www.invacare.com

Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company offers mobility and seating products, such as power wheelchairs under the Invacare TDX brand; custom manual wheelchairs under the Invacare, Invacare Top End, and Küschall brand names; and seating and positioning products under the Invacare brand, as well as custom molded seat modules under the PinDot brand. It also provides lifestyle products, including pressure relieving overlays and mattress systems under the Invacare Softform and microAIR brands; safe patient handling products under the Birdie, Evo, and ISA brands; residential and institutional care beds and bed accessories, and manual wheelchairs under the Invacare brand name; and personal care products.

Invacare Fundamentals Summary

How do Invacare's earnings and revenue compare to its market cap?
IVC fundamental statistics
Market CapUS$48.48m
Earnings (TTM)-US$55.72m
Revenue (TTM)US$877.24m

0.1x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IVC income statement (TTM)
RevenueUS$877.24m
Cost of RevenueUS$645.05m
Gross ProfitUS$232.20m
Other ExpensesUS$287.91m
Earnings-US$55.72m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.56
Gross Margin26.47%
Net Profit Margin-6.35%
Debt/Equity Ratio164.7%

How did IVC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is IVC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IVC?

Other financial metrics that can be useful for relative valuation.

IVC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.4x
Enterprise Value/EBITDA24.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does IVC's PS Ratio compare to its peers?

IVC PS Ratio vs Peers
The above table shows the PS ratio for IVC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.5x
EAR Eargo
1.7x15.8%US$32.2m
SONX Sonendo
1.3x36.2%US$45.7m
RWLK ReWalk Robotics
10.4x37.2%US$57.6m
TRIB Trinity Biotech
0.5x0.6%US$45.8m
IVC Invacare
0.06x2.5%US$48.5m

Price-To-Sales vs Peers: IVC is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (3.5x).


Price to Earnings Ratio vs Industry

How does IVC's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: IVC is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Medical Equipment industry average (3.8x)


Price to Sales Ratio vs Fair Ratio

What is IVC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IVC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.06x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: IVC is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).


Share Price vs Fair Value

What is the Fair Price of IVC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IVC ($1.36) is trading below our estimate of fair value ($9.56)

Significantly Below Fair Value: IVC is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IVC's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Invacare forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


65.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IVC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IVC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IVC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IVC's revenue (2.5% per year) is forecast to grow slower than the US market (8.3% per year).

High Growth Revenue: IVC's revenue (2.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IVC's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Invacare performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


10.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IVC is currently unprofitable.

Growing Profit Margin: IVC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IVC is unprofitable, but has reduced losses over the past 5 years at a rate of 10.5% per year.

Accelerating Growth: Unable to compare IVC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IVC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: IVC has a negative Return on Equity (-29.43%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Invacare's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IVC's short term assets ($350.5M) exceed its short term liabilities ($233.2M).

Long Term Liabilities: IVC's short term assets ($350.5M) do not cover its long term liabilities ($444.8M).


Debt to Equity History and Analysis

Debt Level: IVC's net debt to equity ratio (137.1%) is considered high.

Reducing Debt: IVC's debt to equity ratio has increased from 36.9% to 164.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IVC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if IVC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Invacare current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IVC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IVC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IVC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IVC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: IVC is not paying a notable dividend for the US market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IVC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Matt Monaghan (53 yo)

7.17yrs

Tenure

US$5,993,236

Compensation

Mr. Matthew E. Monaghan, also known as Matt, has been the Chief Executive Officer and President of Invacare Corporation since April 01, 2015 and has been its Chairman of the Board since May 14, 2015. Mr. M...


CEO Compensation Analysis

Compensation vs Market: Matt's total compensation ($USD5.99M) is above average for companies of similar size in the US market ($USD759.63K).

Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: IVC's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: IVC's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Invacare Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Invacare Corporation
  • Ticker: IVC
  • Exchange: NYSE
  • Founded: 1885
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$48.482m
  • Shares outstanding: 35.65m
  • Website: https://www.invacare.com

Number of Employees


Location

  • Invacare Corporation
  • One Invacare Way
  • Elyria
  • Ohio
  • 44035-4190
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.